Cronos Group Inc.

NASDAQ:CRON

Drug Manufacturers - Specialty & Generic

Healthcare
$3.17 -0.56%

-$0.02 today

Market cap
$1.16B
Beta
1.25
P/E (TTM)
-488.3
EPS (TTM)
-$0.01
52W Low $1.84High $3.43

Volume 1.13M

Average 1.51M

CRON Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Cronos Group Inc.NASDAQ: CRON

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 41.4%

Gross margin was 41.4% in Q1 FY2026, down 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 32.8%, up 5.2 pp year over year. Over 3 fiscal years it widened by 23.6 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
41.4%+23.7 pp QoQ
Last fiscal yearDec 2025
41.4%+19.9 pp YoY
LTMMar 2026
32.8%+5.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.1 pp——
1 year+19.9 pp——
3 years+23.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
41.4%
Year-over-year change
+19.9pp

Gross Margin vs competitors

How CRON compares with its peers on the latest reported figures

  • CRON's LTM Mar 2026 gross margin of 32.8% is the lowest of the 10 companies compared; the peer median is 76.8%.
  • Its year-over-year change of +5.2 pp is the 2nd highest of 9, against a peer median of -0.6 pp.
  • Over three fiscal years its change of +23.6 pp compares with a peer median of +9.3 pp.
CRON Competitors Peer median
Gross Margin for CRON and competitors
Company Period LTM level YoY 3-year change
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202695.0% ——
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
PHATPhathom Pharmaceuticals, Inc.LTM Mar 202684.9% -1.3 pp—
PCRXPacira BioSciences, Inc.LTM Mar 202679.3% +1.7 pp+9.3 pp
IRMDIRadimed CorporationLTM Mar 202676.8% -0.1 pp-0.7 pp
EMBCEmbecta Corp.LTM Mar 202662.5% -1.2 pp-5.7 pp
COLLCollegium Pharmaceutical, Inc.LTM Mar 202660.7% +3.0 pp+14.2 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.3% -3.3 pp-0.4 pp
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
CRONCronos Group Inc.LTM Mar 202632.8% +5.2 pp+23.6 pp
BBOTBridgeBio Oncology Therapeutics Inc.FY2025— ——
Peer median (excluding CRON) 76.8%-0.6 pp+9.3 pp

Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue64.56M86.75M87.24M117.62M149.15M
Cost of Revenue82.15M71.31M75.33M92.42M87.45M
Gross Profit(17.59M)15.44M11.91M25.2M61.7M
Gross Margin-27.3%17.8%13.7%21.4%41.4%
Research & Development21.84M13.13M5.84M4.23M4.45M
Selling, General & Admin121.68M100.73M80.93M76.82M63.76M
Operating Expenses274.38M126.86M96.71M101.73M79.54M
Depreciation & Amortization15.4M13.12M8.11M9.34M14.48M
EBITDA(150.13M)(91.27M)(71.8M)(50.21M)(3.36M)
EBITDA Margin-232.5%-105.2%-82.3%-42.7%-2.3%
Operating Income(291.97M)(111.43M)(84.8M)(76.53M)(17.84M)
Operating Margin-452.2%-128.4%-97.2%-65.1%-12.0%
Interest Income9.07M22.51M51.24M52.02M40.66M
Interest Expense27K13K000
Other Income / Expenses163.46M(9.58M)11.13M113.12M419.21K
Income Before Tax(128.51M)(121M)(73.67M)36.59M(17.42M)
Pre-Tax Margin-199.1%-139.5%-84.4%31.1%-11.7%
Income Tax Expense(431K)34.18M(3.23M)(3.44M)(14.44M)
Net Income(396.11M)(168.73M)(73.96M)41.08M(9.61M)
Net Margin-613.5%-194.5%-84.8%34.9%-6.4%
EPS (Basic)(1.07)(0.45)(0.19)0.11(0.03)
EPS (Diluted)(1.07)(0.45)(0.19)0.11(0.03)
Weighted Avg Shares370.39M376.96M403.4M382.06M385.31M
Weighted Avg Shares (Diluted)370.39M376.96M380.97M385.56M385.31M

Cronos Group Inc.

NASDAQ:CRON

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.